The Searle Co Ltd SEARL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 588.22M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 19.05
- Price/Sales
- 1.30
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 1.26%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
The Searle Co Ltd is principally engaged in the manufacturing and sale of pharmaceutical, consumer health, and nutritional products. It manufactures and sells products such as Semavi, Dalimab, Extor, Tramal, Rotec, Hylixi, Emsyn, and many more, focusing on various therapeutic areas like cardiovascular, antibiotics, nutrition, respiratory care, gastroenterology, oncology, hepatology, neurology and psychiatry, probiotics, antibiotics, and nutritional care. Additionally, the group offers medical devices and disposables, health supplements, and various nutritional consumable products. The majority of the group's revenue consists of pharmaceutical sales. Geographically, it generates maximum revenue from Pakistan, and rest from Sri Lanka, Cambodia, Myanmar, Oman, Vietnam, and other countries.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 3,799
- Website
- https://www.searlecompany.com
Valuation
|
Metric
|
SEARL
|
|---|---|
Price/Earnings (Normalized) | 19.05 |
Price/Book Value | 1.36 |
Price/Sales | 1.30 |
Price/Cash Flow | 10.12 |
Price/Earnings
SEARL
Financial Strength
|
Metric
|
SEARL
|
|---|---|
Quick Ratio | 1.35 |
Current Ratio | 1.81 |
Interest Coverage | 5.37 |
Quick Ratio
SEARL
Profitability
|
Metric
|
SEARL
|
|---|---|
Return on Assets (Normalized) | 4.38% |
Return on Equity (Normalized) | 6.68% |
Return on Invested Capital (Normalized) | 6.81% |
Return on Assets
SEARL
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|#<F^Lhm | LOCK|L$<R | $68B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|C<D@wT& | LOCK|F%W^ | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|RF^Dc$N | LOCK|h$ | $39B | |||
| Zoetis Inc Class A
ZTS
| LOCK|&b@Py$XS | LOCK|#M | $29B | |||
| Viatris Inc
VTRS
| LOCK|!!GssJ | LOCK|X< | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|c> | LOCK|GN | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|nR$^>l | LOCK|$TL | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|$@@!>h& | LOCK|#C@ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|^dg!^#& | LOCK|bF#! | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|Dxn!$P | LOCK|!vh | $2B |
United States